Medpace Holdings (MEDP) Peer Comparison
$618.66
As on 20-Nov-2026 12:36EST
Market cap
$18,292 Mln
Revenue (TTM)
$2,838 Mln
P/E Ratio
36.3
P/B Ratio
31.4
Div. Yield
0 %
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
18,292 | 18,064 | 16,837 | 11,432 | 10,891 |
Revenue ($ Mln) |
2,838 | 1,208 | 2,497 | 1,802 | 102 |
Net Profit ($ Mln) |
517.83 | 890.37 | 885.14 | 485.42 | -349.47 |
Net Margin (%) |
18.24 | 73.69 | 35.45 | 26.93 | -341.87 |
RoE (%) |
87.53 | 88.40 | 46.96 | -- | -22.16 |
Price to Earnings |
36.31 | 18.11 | 20.66 | 25.19 | -- |
Price-To-Book |
31.41 | 10.44 | 9.18 | 97.15 | 6.72 |
Income Statement ($ Mln)
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,838.39 | 1,208.20 | 2,496.86 | 1,802.45 | 102.23 |
|
Cost of Revenue
|
2,011.22 | 113.42 | 93.32 | 319.65 | -74.16 |
|
Gross Profit
|
760.62 | 588.53 | 2,236.43 | 1,167.84 | 39.20 |
|
Operating Expenses
|
220.03 | 872.49 | 1,400.14 | 474.96 | 583.29 |
|
Operating Profit (EBIT)
|
607.14 | 222.29 | 1,003.39 | 1,007.84 | -404.89 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
626.99 | 271.18 | 1,065.84 | 655.01 | -349.70 |
|
Provision for Tax
|
109.17 | -619.19 | 180.70 | 169.59 | 0.00 |
|
Profit after Tax (Net Income)
|
517.83 | 890.37 | 885.14 | 485.42 | -349.47 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
584.94 | 1,525.85 | 1,833.83 | -55.24 | 1,614.53 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
221.56 | 384.05 | 267.78 | 3,052.50 | 63.02 |
|
Current Liabilities
|
1,496.10 | 558.37 | 411.88 | 476.09 | 89.72 |
|
Total Liabilities
|
1,975.47 | 1,302.02 | 2,844.42 | 2,525.32 | 1,742.81 |
Assets ($ Mln)
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,057.60 | 854.45 | 1,191.87 | 1,626.62 | 768.68 |
|
Current Assets
|
1,245.00 | 1,613.82 | 1,321.62 | 1,846.73 | 998.59 |
|
Total Assets
|
1,975.47 | 1,302.02 | 2,844.42 | 2,525.32 | 1,742.81 |
|
Total Debt*
|
146.04 | 455.38 | 162.20 | 3,250.30 | 76.60 |
|
Net Current Assets
|
-251.10 | 1,037.87 | 909.75 | 1,370.64 | 908.87 |
Cashflow ($ Mln)
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
713.22 | 51.77 | 884.27 | 651.56 | -232.89 |
|
Cash Flow from Investing Activities
|
-31.14 | -8.15 | 350.44 | -545.81 | -521.06 |
|
Cash from Financing Activities
|
-860.39 | 34.89 | -969.59 | -85.17 | 990.71 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
57.43 | -30.01 | 32.82 | 15.61 | -24.09 |
|
ROE (%)
|
87.53 | 88.40 | 46.96 | 153.59 | -22.16 |
|
ROA (%)
|
15.15 | 34.34 | 28.91 | 13.85 | -23.06 |
|
EBIT Margin (%)
|
21.70 | 20.00 | 42.02 | 37.56 | -341.82 |
|
Net Margin (%)
|
18.24 | 73.69 | 35.45 | 26.93 | -341.87 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
20.35 | 86.87 | 9.12 | 45.03 | 133.74 |
|
EBIT Growth (%)
|
18.61 | 260.53 | 23.13 | -11.34 | -18.50 |
|
Net Profit Growth (%)
|
19.59 | 482.23 | 30.57 | -18.48 | -18.42 |
|
EPS Growth (%)
|
28.28 | 453.25 | 38.78 | -17.34 | -2.42 |
|
Book Value Growth (%)
|
108.60 | 878.06 | -7.57 | -110.94 | 48.81 |
Valuation Ratios
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
36.06 | -59.76 | 15.79 | 24.99 | -21.09 |
|
Price / Book Value
|
35.44 | -80.42 | 5.72 | 162.23 | 4.16 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
27.88 | -121.54 | 12.44 | 17.31 | -19.14 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.25 | 0.00 | -53.31 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.05 | 0.00 | -5.53 | 0.01 |
|
Current Ratio
|
0.83 | 2.89 | 3.21 | 3.88 | 11.13 |
|
Quick Ratio
|
0.83 | 2.29 | 3.14 | 3.60 | 11.13 |
|
Interest Coverage
|
-- | 2.74 | -- | 30.70 | -1,279.94 |
Operating Efficiency Ratios
| Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Kymera Therapeutics (KYMR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
15.77 | 21.41 | 13.16 | 29.16 | 0.00 |
|
Asset Turnover
|
0.83 | 0.47 | 0.82 | 0.51 | 0.07 |
|
Receivable days
|
50.42 | 85.52 | 43.48 | 98.04 | 8.82 |
|
Inventory Days
|
-- | 1,056.70 | 96.17 | 254.12 | -- |
|
Payable days
|
6.26 | 331.01 | 147.97 | 24.86 | -- |
|
Cash Conversion Cycle
|
-- | 811.21 | -8.32 | 327.29 | -- |